Karolinska Development AB (publ) (KDEV.ST)
SEK 1.07
(3.5%)
SEK 1.07
(3.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.01 Million SEK | 22.04% |
| 2022 | 2.3 Million SEK | 5.99% |
| 2021 | 2.17 Million SEK | -18.14% |
| 2020 | 2.65 Million SEK | -21.66% |
| 2019 | 3.38 Million SEK | 10.12% |
| 2018 | 3.07 Million SEK | 24.72% |
| 2017 | 2.46 Million SEK | -54.03% |
| 2016 | 5.36 Million SEK | 82.19% |
| 2015 | 2.94 Million SEK | -41.51% |
| 2014 | 5.03 Million SEK | -49.4% |
| 2013 | 9.94 Million SEK | -0.03% |
| 2012 | 9.94 Million SEK | -5.11% |
| 2011 | 10.47 Million SEK | -24.58% |
| 2010 | 13.89 Million SEK | -54.17% |
| 2009 | 30.32 Million SEK | 1205.77% |
| 2008 | 2.32 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.19 Million SEK | 220.11% |
| 2024 Q2 | 567 Thousand SEK | -59.21% |
| 2023 FY | 2.8 Million SEK | 22.04% |
| 2023 Q4 | 373 Thousand SEK | -9.47% |
| 2023 Q3 | 412 Thousand SEK | -20.92% |
| 2023 Q1 | 548 Thousand SEK | -2.49% |
| 2023 Q2 | 521 Thousand SEK | -4.93% |
| 2022 Q4 | 562 Thousand SEK | 6.64% |
| 2022 Q2 | 621 Thousand SEK | 5.25% |
| 2022 Q1 | 590 Thousand SEK | 25.8% |
| 2022 FY | 2.3 Million SEK | 5.99% |
| 2022 Q3 | 527 Thousand SEK | -15.14% |
| 2021 Q3 | 497 Thousand SEK | -13.57% |
| 2021 Q2 | 575 Thousand SEK | -8.59% |
| 2021 Q4 | 469 Thousand SEK | -5.63% |
| 2021 FY | 2.17 Million SEK | -18.14% |
| 2021 Q1 | 629 Thousand SEK | 19.13% |
| 2020 Q1 | 1.1 Million SEK | 51.65% |
| 2020 FY | 2.65 Million SEK | -21.66% |
| 2020 Q3 | 430 Thousand SEK | -26.99% |
| 2020 Q4 | 528 Thousand SEK | 22.79% |
| 2020 Q2 | 589 Thousand SEK | -46.65% |
| 2019 Q2 | 1.03 Million SEK | 14.93% |
| 2019 Q4 | 728 Thousand SEK | 2.1% |
| 2019 FY | 3.38 Million SEK | 10.12% |
| 2019 Q3 | 713 Thousand SEK | -31.38% |
| 2019 Q1 | 904 Thousand SEK | 5.98% |
| 2018 Q3 | 728 Thousand SEK | -3.96% |
| 2018 Q1 | 734 Thousand SEK | -2.26% |
| 2018 FY | 3.07 Million SEK | 24.72% |
| 2018 Q4 | 853 Thousand SEK | 17.17% |
| 2018 Q2 | 758 Thousand SEK | 3.27% |
| 2017 Q1 | 616 Thousand SEK | -83.4% |
| 2017 Q4 | 751 Thousand SEK | 39.85% |
| 2017 Q2 | 560 Thousand SEK | -9.09% |
| 2017 FY | 2.46 Million SEK | -54.03% |
| 2017 Q3 | 537 Thousand SEK | -4.11% |
| 2016 Q1 | 608 Thousand SEK | 19.69% |
| 2016 FY | 5.36 Million SEK | 82.19% |
| 2016 Q3 | 435 Thousand SEK | -28.34% |
| 2016 Q4 | 3.71 Million SEK | 752.87% |
| 2016 Q2 | 607 Thousand SEK | -0.16% |
| 2015 Q3 | 324 Thousand SEK | -71.02% |
| 2015 FY | 2.94 Million SEK | -41.51% |
| 2015 Q1 | 992 Thousand SEK | -37.22% |
| 2015 Q2 | 1.11 Million SEK | 12.7% |
| 2015 Q4 | 508 Thousand SEK | 56.79% |
| 2014 Q2 | 1.1 Million SEK | -11.37% |
| 2014 FY | 5.03 Million SEK | -49.4% |
| 2014 Q4 | 1.58 Million SEK | 44.42% |
| 2014 Q3 | 1.09 Million SEK | -1.17% |
| 2014 Q1 | 1.24 Million SEK | -52.04% |
| 2013 Q4 | 2.6 Million SEK | -5.62% |
| 2013 Q3 | 2.75 Million SEK | 4.43% |
| 2013 Q2 | 2.64 Million SEK | 36.54% |
| 2013 FY | 9.94 Million SEK | -0.03% |
| 2013 Q1 | 1.93 Million SEK | -24.77% |
| 2012 Q2 | 3.07 Million SEK | 24.2% |
| 2012 Q1 | 2.47 Million SEK | -26.43% |
| 2012 Q4 | 2.57 Million SEK | 41.16% |
| 2012 Q3 | 1.82 Million SEK | -40.73% |
| 2012 FY | 9.94 Million SEK | -5.11% |
| 2011 Q1 | 2.9 Million SEK | 0.0% |
| 2011 Q4 | 3.36 Million SEK | 73.76% |
| 2011 FY | 10.47 Million SEK | -24.58% |
| 2011 Q2 | 2.27 Million SEK | -21.48% |
| 2011 Q3 | 1.93 Million SEK | -15.01% |
| 2010 FY | 13.89 Million SEK | -54.17% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 FY | 30.32 Million SEK | 1205.77% |
| 2008 FY | 2.32 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 96.534% |
| Ziccum AB (publ) | 3.74 Million SEK | 46.25% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.673% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 96.011% |
| Mendus AB (publ) | 28.48 Million SEK | 92.93% |
| Genovis AB (publ.) | 158.23 Million SEK | 98.727% |
| Intervacc AB (publ) | 8.01 Million SEK | 74.872% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 53.955% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 98.818% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 95.412% |
| Aptahem AB (publ) | 2.63 Million SEK | 23.441% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -94.589% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -2515.584% |
| Fluicell AB (publ) | 3.33 Million SEK | 39.664% |
| Saniona AB (publ) | 16.84 Million SEK | 88.04% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 87.725% |
| Biovica International AB (publ) | 7.29 Million SEK | 72.373% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -67.415% |
| AcouSort AB (publ) | 10.55 Million SEK | 80.912% |
| Xintela AB (publ) | 78 Thousand SEK | -2482.051% |
| Abliva AB (publ) | 137 Thousand SEK | -1370.073% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 96.503% |
| OncoZenge AB (publ) | 3000.00 SEK | -67033.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -1199.355% |
| CombiGene AB (publ) | 5.54 Million SEK | 63.673% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.833% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.883% |
| Corline Biomedical AB | 25.03 Million SEK | 91.954% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 64.53% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -179.334% |
| I-Tech AB | 120.86 Million SEK | 98.334% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 98.498% |
| Cyxone AB (publ) | 5.14 Million SEK | 60.878% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 71.433% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 81.115% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 82.066% |
| Nanologica AB (publ) | 1.44 Million SEK | -39.57% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -3700.0% |
| BioInvent International AB (publ) | 71.46 Million SEK | 97.182% |
| Alzinova AB (publ) | 270 Thousand SEK | -645.926% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 94.282% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -37.66% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 28.632% |
| Simris Alg AB (publ) | 4.35 Million SEK | 53.744% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -1449.231% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.156% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -8656.522% |